{"log_id": 4060872964357031913, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.006475, "average": 0.984224, "min": 0.433041}, "location": {"width": 930, "top": 149, "height": 48, "left": 151}, "words": "的暴露量增高60倍(范围12~412)。因此,本品禁止与强效CYPA2抑制剂(如:氟伏沙明、环丙沙"}, {"probability": {"variance": 0.001106, "average": 0.975921, "min": 0.918861}, "location": {"width": 125, "top": 217, "height": 25, "left": 153}, "words": "星)联合使用"}, {"probability": {"variance": 0.000515, "average": 0.994287, "min": 0.845757}, "location": {"width": 888, "top": 245, "height": 47, "left": 194}, "words": "本品与雌激素(中度CYP1A2抑制剂)合用时,阿戈美拉汀的暴露量会增高数倍。尽管800名同"}, {"probability": {"variance": 2e-06, "average": 0.9988, "min": 0.991224}, "location": {"width": 932, "top": 293, "height": 48, "left": 151}, "words": "时使用雌激素的患者均未显示出特异的安全性问题,在获得进一步临床经验前,同时处方阿戈美拉汀和"}, {"probability": {"variance": 0.001011, "average": 0.993572, "min": 0.788536}, "location": {"width": 854, "top": 342, "height": 46, "left": 152}, "words": "中度CYP1A2抑制剂(如:普奈洛尔、格帕沙星、依诺沙星)时应谨慎(参见【注意事项】)"}, {"probability": {"variance": 8e-06, "average": 0.998447, "min": 0.989636}, "location": {"width": 855, "top": 389, "height": 46, "left": 194}, "words": "利福平是所有参与阿戈美拉汀代谢的三种细胞色素的诱导剂,会降低阿戈美拉汀的生物利用度"}, {"probability": {"variance": 0.002408, "average": 0.987819, "min": 0.669228}, "location": {"width": 890, "top": 436, "height": 48, "left": 194}, "words": "吸烟可诱导CYP1A2,会降低阿戈美拉汀的生物利用度,尤其是重度吸烟者(>15支/天)(参见"}, {"probability": {"variance": 0.000206, "average": 0.991404, "min": 0.954453}, "location": {"width": 154, "top": 501, "height": 27, "left": 161}, "words": "【药代动力学】)"}, {"probability": {"variance": 5.6e-05, "average": 0.99675, "min": 0.969788}, "location": {"width": 335, "top": 545, "height": 35, "left": 152}, "words": "阿戈美拉汀对其它药物的潜在影响:"}, {"probability": {"variance": 0.0003, "average": 0.994341, "min": 0.915069}, "location": {"width": 887, "top": 579, "height": 46, "left": 197}, "words": "体内研究,阿戈美拉汀对CYP450同工酶没有诱导作用。阿戈美拉汀对 CYPIA2酶(体内)和其"}, {"probability": {"variance": 0.000172, "average": 0.993667, "min": 0.938416}, "location": {"width": 872, "top": 627, "height": 45, "left": 155}, "words": "它CYP450(体外)没有抑制作用。因此,阿戈美拉汀不会改变经CYP450代谢的药物的暴露量"}, {"probability": {"variance": 1e-06, "average": 0.999521, "min": 0.994674}, "location": {"width": 382, "top": 684, "height": 38, "left": 155}, "words": "与高血浆蛋白结合率药物之间的相互作用"}, {"probability": {"variance": 3.3e-05, "average": 0.998183, "min": 0.966437}, "location": {"width": 672, "top": 725, "height": 42, "left": 196}, "words": "阿戈美拉汀对高血浆蛋白结合率药物的游离药物浓度没有影响,反之亦然"}, {"probability": {"variance": 1e-05, "average": 0.997948, "min": 0.992566}, "location": {"width": 86, "top": 787, "height": 28, "left": 156}, "words": "其它药物"}, {"probability": {"variance": 0.00145, "average": 0.992074, "min": 0.746875}, "location": {"width": 885, "top": 816, "height": 46, "left": 200}, "words": "在1期临床试验中,未发现阿戈美拉汀在目标人群中与其它可能联合使用的药物有药动或药效方面"}, {"probability": {"variance": 7.8e-05, "average": 0.996772, "min": 0.95079}, "location": {"width": 755, "top": 867, "height": 43, "left": 156}, "words": "相互作用的证据,这些药物包括:苯二氮卓类药,锂盐,帕罗西汀,氟康唑和茶碱"}, {"probability": {"variance": 4e-06, "average": 0.998444, "min": 0.995605}, "location": {"width": 57, "top": 932, "height": 25, "left": 156}, "words": "酒精:"}, {"probability": {"variance": 2e-06, "average": 0.99859, "min": 0.996207}, "location": {"width": 232, "top": 973, "height": 30, "left": 200}, "words": "本品不可与酒精同时使用"}, {"probability": {"variance": 0.000143, "average": 0.9934, "min": 0.959831}, "location": {"width": 179, "top": 1024, "height": 29, "left": 156}, "words": "电抽搐治疗(ECT)"}, {"probability": {"variance": 0.00026, "average": 0.995671, "min": 0.897116}, "location": {"width": 888, "top": 1054, "height": 47, "left": 198}, "words": "尚无ECT和阿戈美拉汀同时使用的治疗经验。动物试验中也未显示阿戈美拉汀有致惊厥特性(参"}, {"probability": {"variance": 2e-06, "average": 0.999132, "min": 0.994497}, "location": {"width": 715, "top": 1107, "height": 42, "left": 158}, "words": "见【药理毒理】)。因此认为同时使用阿戈美拉汀和电抽搐治疗不会加强效果"}, {"probability": {"variance": 1e-06, "average": 0.999441, "min": 0.997234}, "location": {"width": 130, "top": 1169, "height": 27, "left": 158}, "words": "儿童和青少年"}, {"probability": {"variance": 1e-06, "average": 0.99913, "min": 0.996685}, "location": {"width": 346, "top": 1210, "height": 30, "left": 200}, "words": "仅对成人进行了药物相互作用的研究。"}, {"probability": {"variance": 8e-06, "average": 0.996537, "min": 0.992231}, "location": {"width": 114, "top": 1263, "height": 26, "left": 165}, "words": "【药物过量】"}, {"probability": {"variance": 0, "average": 0.999955, "min": 0.999923}, "location": {"width": 45, "top": 1312, "height": 27, "left": 159}, "words": "症状"}, {"probability": {"variance": 4e-05, "average": 0.997587, "min": 0.958822}, "location": {"width": 877, "top": 1339, "height": 48, "left": 200}, "words": "服用阿戈美拉汀过量的经验有限。过量服用本品报告有上腹疼痛、嗜睡、疲劳、激越、焦虑、紧张"}, {"probability": {"variance": 0, "average": 0.999442, "min": 0.998532}, "location": {"width": 169, "top": 1404, "height": 31, "left": 159}, "words": "头晕、紫绀和不适"}, {"probability": {"variance": 1e-06, "average": 0.999029, "min": 0.996262}, "location": {"width": 736, "top": 1437, "height": 47, "left": 201}, "words": "曾有人服用了2450mg的阿戈美拉汀,后其自行恢复,未见心血管和生物学异常"}, {"probability": {"variance": 0, "average": 0.999428, "min": 0.998866}, "location": {"width": 45, "top": 1506, "height": 27, "left": 159}, "words": "治疗"}, {"probability": {"variance": 1.3e-05, "average": 0.998354, "min": 0.984558}, "location": {"width": 890, "top": 1532, "height": 45, "left": 201}, "words": "尚无阿戈美拉汀的特效解毒剂。阿戈美拉汀过量的处理应当包括对症治疗和常规监测。建议在专业"}], "language": 3}